Skip to content
value.today
iBio, Inc. logo

iBio, Inc.

IBIO
$59 Mmarket cap on Oct 9, 2026+1872.0% since Jan 2024
Compare
World rank
#20,697
Revenue
$0 M
For year ending June-2026
Net income
$-33 M
-33040.0% margin
SEC filing
Employees
—

iBio, Inc. in brief

iBio, Inc. is a listed company in the Biotechnology industry, based in Delaware, USA. Its market value was $59 M on 9 October 2026, which makes it the 20,697th largest listed company in the world and the 3,786th largest in the USA on this site. In the year to June 2026 it had sales of $0 M and a net loss of $33 M. Its largest product and service lines by sales in 2026 were Collaborative Revenues (100%). Its shares trade under the symbol IBIO (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About iBio, Inc.

iBio, Inc is a Biotechnology company focused on contract development and manufacturing services as well as deploying them for the advancement of own pipeline of therapeutics, vaccines and products for research and bioprocessing applications. The company annual revenue is 2.3 million USD and total assets are 146.9 million USD as on 2021. The headquarters is in USA.

iBio, Inc. timeline

4 events, 2008–2021
  1. 2008
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. ✎
    Renamed iBioPharma, Inc.
    Formerly InB:Biotechnologies, Inc..
  4. 2009
  5. ✎
    Renamed iBio, Inc.
    Formerly iBioPharma, Inc..
  6. 2021
  7. 💰
    Record revenue of $2 million
    FY2021, the highest of the 8 years on record.

Events of iBio, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$31 M$62 M$92 M$123 M2023202420252026

World rank over time

▲ up 1,380 places since 2022
2022-01-07: #22161#22,16120222022-12-25: #32977#32,97720222023-07-30: #31933#31,93320232024-01-05: #33022#33,02220242026-03-08: #10118#10,11820262026-08-01: #18412#18,41220262026-10-09: #20781#20,7812026

Rank in USA: #4,306 (Jan 2022) · #5,809 (Dec 2022) · #5,458 (Jul 2023) · #4,685 (Jan 2024) · #1,962 (Mar 2026) · #3,602 (Aug 2026) · #3,767 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
591.6×
Price / book
0.7×
Free cash flow yield
-40.2%
Net margin
-33040.0%
Operating margin
-35140.0%
Return on equity
-38.5%
Liabilities / assets
13.5%
Revenue growth
-75.0%
R&D / revenue
19640.0%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Jun 2019: revenue $2M, net income $-18M$2MFY19Fiscal year ending Jun 2020: revenue $2M, net income $-16M$2MFY20Fiscal year ending Jun 2021: revenue $2M, net income $-23M$2MFY21Fiscal year ending Jun 2022: revenue $2M, net income $-50M$2MFY22Fiscal year ending Jun 2023: revenue —, net income $-65M—FY23Fiscal year ending Jun 2024: revenue $0M, net income $-25M$0MFY24Fiscal year ending Jun 2025: revenue $0M, net income $-18M$0MFY25Fiscal year ending Jun 2026: revenue $0M, net income $-33M$0MFY26
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Jun 2026$0M-75.0%$-35M$-33M-33040.0%
Jun 2025$0M+81.8%$-19M$-18M-4595.0%
Jun 2024$0M—$-17M$-25M-11322.7%
Jun 2023——$-29M$-65M—
Jun 2022$2M-20.7%$-30M$-50M-2675.5%
Jun 2021$2M+44.5%$-31M$-23M-979.3%
Jun 2020$2M-18.8%$-14M$-16M-1002.4%
Jun 2019$2M—$-16M$-18M-870.8%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Jun 2026$-23M$1M$-24M$-0.32—
Jun 2025$-15M$0M$-15M$-1.75—
Jun 2024$-19M$0M$-19M$-6.50—
Jun 2023$-30M$6M$-36M$-106.19—
Jun 2022$-37M$7M$-45M$-5.78—
Jun 2021$-30M$5M$-35M$-3.00—
Jun 2020$-13M$1M$-14M$-0.61—
Jun 2019$-14M$1M$-15M$-0.94—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024: revenue $0M, net income $-4M$0MDec ’24Three months to Mar 2025: revenue —, net income $-5M—Mar ’25Three months to Jun 2025 (from the annual report): revenue —, net income $-5M—Jun ’25Three months to Sep 2025: revenue $0M, net income $-6M$0MSep ’25Three months to Dec 2025: revenue —, net income $-9M—Dec ’25Three months to Mar 2026: revenue —, net income $-8M—Mar ’26Three months to Jun 2026 (from the annual report): revenue —, net income $-11M—Jun ’26Three months to Sep 2026: revenue $1M, net income $-8M$1MSep ’26

Latest quarter to Sep 2026: revenue $1M (+980.0% on a year earlier), net income $-8M. Lighter bars: fourth quarters worked out from the annual report.

SEC filings

Official filings of iBio, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$0 M
Operating income
$-35 M
Net income
$-33 M

For year ending June-2026 · source: SEC filing

Balance sheet

Total assets
$99 M
Total liabilities
$13 M
Total equity
$86 M

As of June-2026

Top 60 institutional investors in iBio, Inc.#

As of Sep 30, 2026
60 institutions held 37.5 M shares (about 58.3% of the shares outstanding) on Sep 30, 2026. The ten largest hold 41.4%. Source: SEC Form 13F filings, filed through Nov 18, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in iBio, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Silverarc Capital Management, LLC5,357,088+1,836,598 (+52.17%)8.33%$6 MNov 12, 2026
2Affinity Asset Advisors, LLC4,130,427+122,546 (+3.06%)6.42%$5 MNov 13, 2026
3Cormorant Asset Management, LP3,570,0000 (0.00%)5.55%$4 MNov 16, 2026
4Vestal Point Capital, LP2,600,0000 (0.00%)4.04%$3 MNov 16, 2026
5Woodline Partners LP2,238,450+461,903 (+26.00%)3.48%$3 MNov 16, 2026
6Vanguard Capital Management LLC2,098,1510 (0.00%)3.26%$2 MNov 13, 2026
7Frazier Life Sciences Management, L.P.1,953,4670 (0.00%)3.04%$2 MNov 16, 2026
8Balyasny Asset Management L.P.1,592,008+421,115 (+35.97%)2.48%$2 MNov 16, 2026
9Ensign Peak Advisors, Inc1,565,758-266,699 (-14.55%)2.43%$2 MNov 12, 2026
10Bank Of America Corp /de/1,488,537+367,045 (+32.73%)2.31%$2 MNov 16, 2026
11Millennium Management LLC1,423,043-228,430 (-13.83%)2.21%$2 MNov 16, 2026
12Ikarian Capital, LLC957,0620 (0.00%)1.49%$1 MNov 16, 2026
13Sio Capital Management, LLC904,2680 (0.00%)1.41%$1 MNov 16, 2026
14Atom Investors LP881,558+780,001 (+768.04%)1.37%$1 MNov 16, 2026
15Marshall Wace, LLP766,195-137,937 (-15.26%)1.19%$1 MNov 13, 2026
16Renaissance Technologies LLC688,400+485,553 (+239.37%)1.07%$1 MNov 12, 2026
17Citadel Advisors LLC666,171-717,858 (-51.87%)1.04%$1 MNov 16, 2026
18Geode Capital Management, LLC525,983+25,167 (+5.03%)0.82%$1 MNov 6, 2026
19Walleye Capital LLC400,043-100,332 (-20.05%)0.62%$0 MNov 13, 2026
20ADAR1 Capital Management, LLC375,5310 (0.00%)0.58%$0 MNov 16, 2026
21Sofinnova Investments, Inc.371,700New0.58%$0 MNov 16, 2026
22BlackRock, Inc.291,450+49,434 (+20.43%)0.45%$0 MNov 13, 2026
23Vanguard Fiduciary Trust Co286,8750 (0.00%)0.45%$0 MNov 13, 2026
24Boothbay Fund Management, LLC254,4120 (0.00%)0.40%$0 MNov 16, 2026
25Noesis Capital Mangement Corp249,000-156,000 (-38.52%)0.39%$0 MOct 26, 2026
Show all 60: investors 26 to 60
Institutional investors 26 to 60 in iBio, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Two Sigma Investments, LP240,272-160,395 (-40.03%)0.37%$0 MNov 16, 2026
27State Street Corp218,952+48,153 (+28.19%)0.34%$0 MNov 12, 2026
28Goldman Sachs Group Inc200,308-147 (-0.07%)0.31%$0 MNov 16, 2026
29Verdad Advisers, LP196,818-102,109 (-34.16%)0.31%$0 MNov 16, 2026
30DAFNA Capital Management LLC170,0530 (0.00%)0.26%$0 MNov 16, 2026
31XTX Topco Ltd165,226+107,384 (+185.65%)0.26%$0 MNov 16, 2026
32Morgan Stanley126,250+126,240 (+1262400.00%)0.20%$0 MNov 13, 2026
33Squarepoint Ops LLC112,153-386,719 (-77.52%)0.17%$0 MNov 9, 2026
34Northern Trust Corp111,3190 (0.00%)0.17%$0 MNov 16, 2026
35HRT Financial LP92,676New0.14%$0 MNov 13, 2026
36Landscape Capital Management, L.L.C.88,796New0.14%$0 MNov 10, 2026
37Vanguard Global Advisers, LLC30,356+24,896 (+455.97%)0.05%$0 MNov 13, 2026
38UBS Group AG30,328+29,827 (+5953.49%)0.05%$0 MNov 10, 2026
39R Squared Ltd24,153New0.04%$0 MNov 6, 2026
40Readystate Asset Management LP21,694New0.03%$0 MNov 16, 2026
41Spark Investment Management LLC17,600+4,100 (+30.37%)0.03%$0 MNov 13, 2026
42StoneX Group Inc.16,087New0.03%$0 MNov 3, 2026
43Bank of New York Mellon Corp10,636-1 (-0.01%)0.02%$0 MNov 5, 2026
44Jpmorgan Chase & Co1,436-4,461 (-75.65%)0.00%$0 MNov 12, 2026
45Tower Research Capital LLC (TRC)1,224New0.00%$0 MNov 16, 2026
46Royal Bank Of Canada1,194New0.00%$0 MNov 16, 2026
47Fortitude Family Office, LLC4310 (0.00%)0.00%$0 MOct 14, 2026
48Osaic Holdings, Inc.3800 (0.00%)0.00%$0 MNov 12, 2026
49FMR LLC220-213 (-49.19%)0.00%$0 MNov 10, 2026
50Caitong International Asset Management Co., Ltd60+51 (+566.67%)0.00%$0 MOct 29, 2026
51SBI Securities Co., Ltd.420 (0.00%)0.00%$0 MOct 22, 2026
52SOA Wealth Advisors, LLC.130 (0.00%)0.00%$0 MNov 10, 2026
53Citigroup Inc7New0.00%$0 MNov 4, 2026
54Jones Financial Companies Lllp6New0.00%$0 MNov 13, 2026
55Wells Fargo & Company/mn4-97 (-96.04%)0.00%$0 MNov 16, 2026
56Activest Wealth Management40 (0.00%)0.00%$0 MOct 15, 2026
57Harbour Investments, Inc.3New0.00%$0 MNov 9, 2026
58Robinhood Markets, Inc.3—0.00%$0 MNov 18, 2026
59Barclays PLC2-3,253 (-99.94%)0.00%$0 MNov 6, 2026
60BNP Paribas Financial Markets20 (0.00%)0.00%$0 MNov 12, 2026

Mutual funds holding iBio, Inc.#

12 funds hold shares worth $4 M (about 3.9% of the company). Since their previous reports 10 added shares and 1 sold, buying $2 M net.
Mutual funds holding iBio, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.1.47 M$3 M2.3%<0.01%+118%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.582,071$1 M0.91%<0.01%+47%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC187,860$0 M0.29%<0.01%+51%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors103,831$0 M0.16%0.01%newJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC63,803$0 M0.10%<0.01%+42%May 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC51,345$0 M0.08%<0.01%+62%May 31, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.29,586$0 M0.05%<0.01%newJun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC19,435$0 M0.03%<0.01%+60%May 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.20,661$0 M0.03%<0.01%no changeJun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC6,970$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC654$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC500$0 M<0.01%<0.01%−55%Jun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 12 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at iBio, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$98 K
4 purchases, 3 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$98 K
open market only
Insiders on file
18
since
$580 K-$1 K$0Nov 2023: bought $0 (0 trades), sold $1 K (1 trades)Nov 23Jan 2025: bought $580 K (7 trades), sold $0 (0 trades)Jan 25Mar 2026: bought $98 K (4 trades), sold $0 (0 trades)Mar
Bought (open market)Sold (open market)Hover a month for the totals
iBio, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Marc BanjakChief Legal OfficerBuy+12,500$1.640$21 K23,566Form 4
filed Marc BanjakChief Legal OfficerBuy+1,434$1.760$3 K25,000Form 4
filed Felipe DuranChief Financial OfficerBuy+24,835$2.020$50 K35,974Form 4
filed Martin BrennerSee Remarks, DirectorBuy+12,336$2.020$25 K30,652Form 4
filed William D. ClarkDirectorBuy+1,838$2.720$5 K1,838Form 4
filed Parada Antonio Bernardino GuimaraesDirectorBuyindirect+183,823$2.720$500 K183,823Form 4
filed Gary SenderDirectorBuy+9,191$2.720$25 K9,191Form 4
filed David ArkowitzDirectorBuy+18,382$2.720$50 K18,382Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: iBio, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
4.0 M
7.2% of shares · 7.15 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-20 reverse split ; 1-for-25 reverse split ; 1-for-10 reverse split

Trading halts

  • 2025-12-08 14:38 UTC, code LUDP, resumed 14:43 UTC
  • 2025-04-07 14:59 UTC, code LUDP, resumed 15:04 UTC
  • 2025-04-07 14:42 UTC, code LUDP, resumed 14:47 UTC
  • 2025-04-07 14:29 UTC, code LUDP, resumed 14:39 UTC
  • 2025-04-07 14:23 UTC, code LUDP, resumed 14:28 UTC

Fails to deliver

  • : 68,584 shares at $0.92
  • : 19,654 shares at $1.01
  • : 12,211 shares at $1.40
  • : 22,006 shares at $1.43
  • : 21,321 shares at $1.47

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

iBio, Inc. scorecard#

Passes 2 of the 14 checks that could be worked out: strongest in financial health (1 of 4), weakest in profitability (0 of 3). Fiscal year 2026; market cap of Oct 9, 2026.

  • Valuation1 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median0.7×Price to book 0.7× against Biotechnology's median of 2.9×.
    • ✗Price to sales below its peers' median591.6×Price to sales 591.6× against Biotechnology's median of 8.7×.
    • ✗Free cash flow yield above 5%-40.2%Free cash flow is -40.2% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-0.32 vs -1.75Diluted EPS -0.32 in fiscal 2026 against -1.75 the year before (report's currency).
    • ✗Net income higher than five years earlier-$33 M-$33 M in fiscal 2026 against -$23 M in 2021.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$33 MNet income -$33 M in fiscal 2026.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2026.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-65.7%-65.7% in fiscal 2026.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 4
    • ✓Short-term assets cover short-term liabilities7.9×Current ratio 7.86 at the end of fiscal 2026.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • ✗Operating income covers interest five times-702.8×Operating income -702.8 times interest in fiscal 2026.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2026.
    • ✗Altman Z-score outside the distress zone-2.71Z-score -2.71 (distress zone) for fiscal 2026.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

iBio, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

iBio, Inc.: statements by fiscal year
PeriodTrendFY 2026to Jun 30, 2026FY 2025to Jun 30, 2025FY 2024to Jun 30, 2024FY 2023to Jun 30, 2023FY 2022to Jun 30, 2022FY 2021to Jun 30, 2021FY 2020to Jun 30, 2020FY 2019to Jun 30, 2019FY 2018to Jun 30, 2018FY 2017to Jun 30, 2017
Income statement
Revenue0.10.40.201.9r2.41.62.00.40.4
Cost of revenue————0.21.50.7———
Gross profit————2.20.90.9———
Research and development208.35.2109.8r10.03.6r5.54.04.1
General and administrative1111121922r2211r121111
Operating expenses3519172932r3215r181515
Operating income−35−19−17−29−30r−31−14−16−14−14
Interest and finance income2.20.40.40.20.2r0.10.00.10.00.0
Interest expense and finance costs0.10.20.20.11.42.52.51.91.91.9
Other non-operating income (expense)2.10.21.20.00.2r7.9−2.4−1.8−1.9−1.9
Income before tax−33−18————————
Income tax0000000000
Income from continuing operations———−29−30—————
Income from discontinued operations——−9.5−36−21—————
Net income including minority interests−33−18−25−65−50−23−16−18−16−16
Minority interests' share of net income————−0.0−0.0−0.0−0.0−0.0−1.6
Net income attributable to shareholders−33−18−25−65−50−23−16−18−16−15
Earnings per share, basic-0.32-1.75-6.50-106.19r-5.78-3.00r-0.61-0.94-1.54-1.64r
Earnings per share, diluted-0.32-1.75-6.50-106.19r-5.78-3.00r-0.61-0.94-1.54-1.64r
Shares, weighted average (basic)104103.80.6r8.77.8————
Shares, weighted average (diluted)104103.80.6r8.77.8r6319118.9r
Balance sheet
Cash and cash equivalents568.6144.32377554.4r4.4r16r
Short-term investments3200———————
Receivables—0001.00.40.10.10.10.2
Inventory——003.90.0————
Other current assets3.11.00.70.71.52.10.20.30.30.3
Current assets929.7162645105624.8168.6
Property, plant and equipment3.13.23.64.21.4r8.63.7242526
Right-of-use (leased) assets1.72.12.42.73.1r0————
Other intangible assets1.86.85.45.44.91.01.11.41.61.8
Total assets992329419914794314336
Accounts payable4.42.20.41.84.32.31.81.00.80.7
Current liabilities126.13.822r306.65.23.52.02.0
Lease liabilities (non-current)1.72.22.73.13.5r0————
Total liabilities138.37.426363838282727
Retained earnings−365−332−314−289−224−174−150−106−88−72
Shareholders' equity8615211563109572.5168.9
Minority interests—————−0.0−0.0−0.0−0.00.0
Total equity8615211563109572.5168.9
Total liabilities and equity992329419914794314336
Shares outstanding56198.61.0r8.78.7r14020168.9r
Cash-flow statement
Depreciation and amortization———————0.2——
Share-based compensation1.41.52.04.44.41.60.40.20.81.0
Cash from operating activities−23−15−19−30−37−30−13−14−13−13
Capital expenditure−0.6−0.0−0.2−5.7−7.3−4.9−1.1−0.9−0.9−1.3
Intangible assets bought————−4.3−0.2−0.1−0.1−0.1−0.3
Acquisitions, net of cash acquired———−0.7——————
Cash from investing activities−320.70.97.0−5.1−26−1.2−1.0−1.1−1.6
Shares issued3.53.52611—————0
Cash from financing activities1038.9242.3−6.179653.522−0.2
Exchange-rate effect on cash—————−0.0−0.0−0.0−0.00
Change in cash48−5.66.8−21−492251−127.8−15
Report10-K10-K10-K10-K/A10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What iBio, Inc. sells: revenue by product line, fiscal 2026#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2025. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Collaborative Revenues$0 M100%

Source: SEC annual report (XBRL data) · as of Jun 30, 2026

Executive pay at iBio, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2026
$2.1 M
Dr. Martin B. Brenner
Other top executives, average
$1.0 M
the CEO earned 2.1× this
$100 invested is now
$14
iBio, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2026Dr. Martin B. Brenner$2.1 M$2.3 M$1.0 M$14
2025Chief executive$1.5 M$622 K$741 K$6
2024Chief executive$1.3 M$1.2 M$762 K$17

Source: SEC proxy statement (Form DEF 14A) · as of Jun 30, 2026

Events at iBio, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling

Delisting notice 1 · Directors and officers 3 · Material agreement 4 · Agreement ended 1 · Unregistered share sale 1 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 8

iBio, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Directors and officersBylaws or fiscal year changedShareholder vote8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Material agreementAgreement ended8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Delisting notice8-K
Results announced8-K
Material agreement8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026

Acquisitions and funding#

2 private funding rounds before listing

Private share sales · funding history

Private share sales of iBio, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2026$26 MPrivate placement after listing$10 to $50 million7optionsSEC
Apr 2025$11 MPrivate placement after listing$10 to $50 million5optionsSEC
Mar 2024$15 MPrivate placement after listing$10 to $50 million8equity, optionsSEC
Jan 2016$2 MPrivate placement after listing$2 to $10 million1equitySEC
Oct 2010$7 MNo. 2$2 to $10 million52equity, optionsSEC
Sep 2009$3 MNo. 1$2 to $10 million26equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Lobbying by iBio, Inc.#

$90 K spent on lobbying the US Congress and federal agencies in 2022, most often on health issues, medical/disease research/clinical labs and budget/appropriations.

Lobbying, 2022
$90 K
#1,149 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2022
2026 so far
—
  • Health Issues3 reports
  • Medical/Disease Research/Clinical Labs3 reports
  • Budget/Appropriations3 reports

Lobbying firms hired in 2022

The Petrizzo Group, Inc. $90 K

iBio, Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2022$90 K—3
2021$120 K—6
2020$110 K—4

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “iBio, Inc.” and “IBIO, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

Layoffs at iBio, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
0
2022–2022
Latest
—
2022-10-31
iBio, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2022············—
iBio, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
Not statedRestructuring planSEC 8-KCompany-wide planFiling

Source: State WARN notices and SEC 8-K item 2.05

How iBio, Inc. compares in Biotechnology

  • Market cap$59 M · higher than 29% of 726
  • Revenue$0 M · higher than 16% of 647
  • Revenue growth-75.0% · higher than 8% of 438
  • Price / sales591.6× · lower than 1% of 339
  • Price / book0.7× · lower than 85% of 534
  • FCF yield-40.2% · higher than 28% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
iBio, Inc.🇺🇸$59 M——-75.0%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 9, 2026
Annual results:
For year ending June-2026
Balance sheet:
As of June-2026
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at iBio, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show iBio, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about iBio, Inc.? Suggest a correction